Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer

Patrick Schöffski, B. Thate, Gernot Beutel, O. Bolte, D. Otto, Melanie Hofmann, Arnold Ganser, A. Jenner, Peter Cheverton, J. Wanders,

Annals of Oncology · 2004 · 66 citations · 16 references

DOIFull text

Open access

Concepts

References

16